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Background
Hyperinsulinemia, Diabetes type 2, and obesity have been
identified as increased risk factors for a variety of cancers
[1]. Conversely, insulin inhibition (INSINH) can plausibly
limit cancer growth by demonstrated mechanisms includ-
ing ketosis [2] and regulation of downstream signaling
proteins such as mTOR (inhibition) and AMPK (amplifi-
cation), already in development as drug targets [3,4].
Increased
18F-2-fluoro, 2-deoxyglucose (FDG) uptake on
positron emission tomography (PET) scan is characteristic
of many aggressive malignancies. We examined safety and
feasibility of a four week INSINH diet in patients with
advanced PET positive cancers, and compared exit vs.
baseline PET scan changes as surrogate measures for
tumor response.
Methods
Eligible patients, referred by faculty or self-referred
after locating our trial (e.g. www.clinicaltrials.gov/
NCT00444054), had failed or refused ≥2s t a n d a r dc h e -
motherapy courses and demonstrated FDG-positive scans
on baseline PET. Exclusions included concurrent che-
motherapy, end-organ disease, hypoglycemic medications,
difficult compliance, or BMI < 20. A supervised INSINH
diet restricting starches and sugars for 28 days, was moni-
tored weekly for macronutrient intake, body weight, serum
electrolytes, betahydroxybutyrate concentrations [BHB],
[insulin], [IGF 1,2]. An exit four-week PET was obtained
for comparison with the baseline scan.
Results
Ten subjects with diverse cancers completed > 26 days of
INSINH without associated unsafe adverse effects. Mean
caloric intake decreased (35 ± 6) % vs. predicted require-
ments despite best efforts to encourage increased food
consumption. Weight loss (median 4%, range 0.0-6.1%)
was not judged a health risk in any subject. Mild, reversi-
ble side effects included constipation (n=2), transient fati-
gue (n=5), and leg cramps (n=2). Among nine patients
with rapid pre-trial progressive disease (PD) five demon-
strated post-trial SD or partial remission (SD/ PR) on
PET. SD/PR correlated with three-fold higher ketosis
compared to those with continued PD (n=4), (p<0.02),
but was uncorrelated with reduced calorie intake
(p=0.45) or weight loss (p =0.81). Insulin correlated
inversely with ketosis (r=0.62, p=0.026), but did not cor-
relate with IFG(1 or 2).
Conclusions
Preliminary pilot data in ten subjects demonstrated that
an INSINH diet is safe and feasible in selected patients
with advanced cancer. The extent of ketosis, but neither
calorie deficit nor weight loss correlated with SD/PR.
The small sample size requires cautious interpretation.
Further evaluation is needed to explore the relation of
insulin inhibition to calorie restriction, as well as a
potential therapeutic role of diet adjunctive to metabolic
or cytotoxic therapies.
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